WuXi PharmaTech reported another year of steadily increasing growth for 2012, something it seems to do with metronomic regularity. In 2012, the company’s net revenues rose 23% to just under $500 million and earnings (GAAP) climbed 7% to $86.6 million. WuXi’s mainstay business, China-based laboratory services, led the charge, rising almost 27% to $293 million. Manufacturing revenues increased 22.5% to $117 million, and US laboratory services were up 12% to $90 million. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //